Drug Information Association Logo

Complimentary Biomarker Strategies for More Efficient Early-Phase Drug Development in Alzheimer's Disease

| Online

« Back to Listing


This Solution Provider Archived Webinar is brought to you by DIA in cooperation with ICON plc. Registration for Solution Provider Webinars is FREE!  Sign up by clicking on the Register Online button.

Alzheimer's disease is the most common form of dementia affecting millions of individuals worldwide.   The development of validated biomarkers for Alzheimer's disease is essential to improve early diagnosis and accelerate the development of new therapies – aiding in understanding the mechanism of action of a drug, identifying efficacy or toxicity signals at an early stage of development and in identifying patients likely to respond to treatment. Biochemical and neuroimaging markers can facilitate diagnosis, predict AD progression from a pre-AD state of mild cognitive impairment (MCI), and monitor efficacies of disease-modifying therapies.

ICON is the first to collaborate with DIA’s newly-created Solution Provider Webinar Program. This archived webinar is the second in a series of four that will bring together leading scientists and thought leaders from the biopharma industry. Additional topics to be featured will be strategies for late phase development and technology as an enabler of clinical development services.

Please note: Continuing education credits and certificate program units are not available for archived webinars.

This archived webinar will be available through May 22, 2014.

Featured Topics 

  • Drug Development in Alzheimer's Disease: Using Data Analytics to Turn Challenges into Opportunities
  • The Use of Molecular Markers in CSF and Plasma in Alzheimer Disease – The Laboratory Perspective
  • Advances in Imaging Biomarkers in AD Drug Development to Enable Accelerated Approval - Fluorodeoxyglucose PET and Functional MRI
  • Recent FDA Draft Guidance on Developing Drugs for Alzheimer’s Disease - Key Considerations

Who Should Attend 

Professional who work in the area of:

  • Translational Medicine
  • Experimental Medicine
  • Personalized Medicine
  • Biomarkers
  • Clinical Operations
  • Regulatory Affairs
  • CNS
  • Alzheimer's disease
  • Imaging
  • Medical Affairs
  • Drug Safety & Pharmacovigilance
  • Outsourcing

Learning Objectives 

At the conclusion of this webinar, participants should be able to:

  • Define biomarker strategies for more efficient early-phase drug development in Alzheimer’s disease
  • Identify potential issues and resolutions for the analytical laboratory regarding commonly used assays to assess Alzheimer’s disease
  • Discuss the use of advanced imaging methods to support Alzheimer’s disease research

Special Offers 

Registration for Solution Provider Archived Webinars is FREE! Sign up by clicking on the Register Online button.

Contact Information 

Registration Questions
Toll Free 1.888.257.6457
Phone +1.215.6100
Fax +1.215.442.6199
Monday-Friday 8:30AM - 8:00PM ET

Technical Requirements 

Click here for minimum system requirements.


Previous Next


Day 1 Wednesday, May 22, 2013

  • 11:00AM - 11:59PM

    Complimentary Biomarker Strategies for More Efficient Early-Phase Drug Development in Alzheimer's Disease


    • Biomarkers in the Clinical Trial Development of Alzheimer Disease Agents: The Laboratory Perspective
      John Allinson
      VP Biomarker Lab Services
      ICON Development Solutions, United Kingdom
    • CSF, MRI and PET Biomarkers in AD Trials; A Clinical Perspective
      Niels Prins, MD, PhD, MSc
      Alzheimer Research Center (ARC), Netherlands
    • Complex Diseases: Biomarkers, Drugs and Clinical Trials in Alzheimer’s Disease
      Michael N Liebman, PhD
      Managing Director
      IPQ Analytics, United States

Registration Fees 

Other Fees

Register Online

Unless otherwise disclosed, the statements made by speakers represent their own opinions and not necessarily those of the organization they represent, or that of the Drug Information Association. Speakers, agenda and CE information are subject to change without notice. Recording of any DIA educational material in any type of media is prohibited without prior written consent from DIA.

« Back to Listing Back To Top